StonvexLoading…
StonvexStonvexStonvexCore line items from CDNA's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $117.70M | $379.81M | $271.42M | $171.36M |
Operating Income | $1.20M | $-30.78M | $-24.74M | $-24.50M |
Net Income | $2.81M | $-21.35M | $-17.25M | $-8.57M |
EPS (Diluted) | $0.05 | $-0.40 | $-0.32 | $-0.35 |
Total Assets | $411.06M | $413.23M | $432.31M | $444.26M |
Total Liabilities | $97.53M | $110.13M | $121.17M | $116.89M |
Cash & Equivalents | $77.92M | $65.43M | $91.44M | $68.21M |
Free Cash Flow OCF − CapEx | $514.00K | Not available | Not available | Not available |
Shares Outstanding | 51.27M | 50.92M | 51.41M | 53.22M |